Press Releases

Investor and Media Contacts

Investors

DeDe Sheel
650-376-6492
dsheel@aimmune.com

Media

Julie Normart
559-974-3245
jnormart@w2ogroup.com

Lauren Barbiero
646-564-2156
lbarbiero@w2ogroup.com

ShareThis Copy and Paste

Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT

Webcast Presentation

Help

Help

Click here for webcast

— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...